Mild Cognitive Impairment Pipeline Review, H2 2015
Summary
Global Markets Directs, Mild cognitive impairment Pipeline Review, H2 2015, provides an overview of the Mild cognitive impairments therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Mild cognitive impairment, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Mild cognitive impairment and special features on late-stage and discontinued projects.
Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
The report provides a snapshot of the global therapeutic landscape of Mild cognitive impairment
The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
The report reviews key players involved in the therapeutics development for Mild cognitive impairment and enlists all their major and minor projects
The report summarizes all the dormant and discontinued pipeline projects
A review of the Mild cognitive impairment products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
A detailed assessment of monotherapy and combination therapy pipeline projects
Coverage of the Mild cognitive impairment pipeline on the basis of target, MoA, route of administration and molecule type
Latest news and deals relating related to pipeline products
Reasons to buy
Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Develop strategic initiatives by understanding the focus areas of leading companies
Identify and understand important and diverse types of therapeutics under development for Mild cognitive impairment
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Devise corrective measures for pipeline projects by understanding Mild cognitive impairment pipeline depth and focus of Indication therapeutics
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table Of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Mild Cognitive Impairment Overview 9
Therapeutics Development 10
Pipeline Products for Mild Cognitive Impairment - Overview 10
Pipeline Products for Mild Cognitive Impairment - Comparative Analysis 11
Mild Cognitive Impairment - Therapeutics under Development by Companies 12
Mild Cognitive Impairment - Therapeutics under Investigation by Universities/Institutes 13
Mild Cognitive Impairment - Pipeline Products Glance 14
Clinical Stage Products 14
Early Stage Products 15
Mild Cognitive Impairment - Products under Development by Companies 16
Mild Cognitive Impairment - Products under Investigation by Universities/Institutes 17
Mild Cognitive Impairment - Companies Involved in Therapeutics Development 18
Actinogen Limited 18
Avraham Pharmaceuticals Ltd. 19
Boehringer Ingelheim GmbH 20
CereSpir Incorporated 21
D-Pharm Ltd. 22
Eisai Co., Ltd. 23
Eli Lilly and Company 24
Octapharma AG 25
Sage Therapeutics 26
Sanofi 27
Suven Life Sciences Ltd. 28
Mild Cognitive Impairment - Therapeutics Assessment 29
Assessment by Monotherapy Products 29
Assessment by Target 30
Assessment by Mechanism of Action 32
Assessment by Route of Administration 34
Assessment by Molecule Type 36
Drug Profiles 38
BAN-2401 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
BCA-909 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
CSP-1103 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
DAOI-B - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
DP-NDD - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
immune globulin (human) - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
insulin (human) - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
ladostigil tartrate - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
levetiracetam - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
LY-3002813 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
SAGE-547 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
SAR-228810 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Small Molecule to Antagonize nAChR Alpha-4 Beta-2 for CNS Disorders - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
SUVN-501 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
SUVN-502 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
SUVN-507 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
SUVN-512 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
SUVN-976 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
SUVND-4010 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
tropisetron hydrochloride - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
UE-2343 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Mild Cognitive Impairment - Recent Pipeline Updates 69
Mild Cognitive Impairment - Dormant Projects 82
Mild Cognitive Impairment - Dormant Projects 82
Mild Cognitive Impairment - Discontinued Products 84
Mild Cognitive Impairment - Product Development Milestones 85
Featured News & Press Releases 85
Jul 28, 2015: Avraham Pharmaceuticals Announces Successful Second Interim Results in Phase 2b Study of Ladostigil for the Treatment of Mild Cognitive Impairment 85
Jul 14, 2015: CereSpir Obtains New Patent From USPTO Covering the Optimal Synthetic Route for Commercial Manufacture of CSP-1103 in Late Stage Development to Slow the Progression of Mild Cognitive Impairment Due to Alzheimer's Disease 86
Jul 01, 2015: CereSpir Submits Special Protocol Assessment Request to FDA for a Phase 3 Clinical Trial to Test the Ability of CSP-1103 to Slow the Progression of Mild Cognitive Impairment Due to Alzheimer's Disease 86
Jul 08, 2014: Avraham Pharmaceuticals Announces Successful Interim Results in Phase 2b Study of Ladostigil for the Treatment of MCI 87
Jul 26, 2013: CERESPIR INCORPORATED IS PLEASED WITH POSITIVE INTERIM PHASE 2 RESULTS FOR CHF 5074 IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT, PRESENTED BY CHIESI AT THE AAIC 2013 MEETING IN BOSTON 87
May 17, 2012: Avraham Initiates Phase II Ladostigil Study For Treatment Of Mild Cognitive Impairment 88
Apr 14, 2010: Alzheimer Drug Co Avraham Pharmaceuticals Raises $9m 89
Jul 27, 2009: Suven Presented Positive Phase-I Clinical Data Of SUVN-502 For Alzheimer’s Disease At ICAD 2009, Vienna, Austria. 89
Apr 09, 2009: Suven Completes Phase I Clinical Trials Multiple Ascending Dose Of SUVN-502 In Switzerland 90
Oct 13, 2008: Suven Announces That SUVN-502 Data Is Being Presented At 16th BioPartnering In London 91
Appendix 92
Methodology 92
Coverage 92
Secondary Research 92
Primary Research 92
Expert Panel Validation 92
Contact Us 92
Disclaimer 93
List Of Tables
Number of Products under Development for Mild Cognitive Impairment, H2 2015 10
Number of Products under Development for Mild Cognitive Impairment - Comparative Analysis, H2 2015 11
Number of Products under Development by Companies, H2 2015 12
Number of Products under Investigation by Universities/Institutes, H2 2015 13
Comparative Analysis by Clinical Stage Development, H2 2015 14
Comparative Analysis by Early Stage Development, H2 2015 15
Products under Development by Companies, H2 2015 16
Products under Investigation by Universities/Institutes, H2 2015 17
Mild Cognitive Impairment - Pipeline by Actinogen Limited, H2 2015 18
Mild Cognitive Impairment - Pipeline by Avraham Pharmaceuticals Ltd., H2 2015 19
Mild Cognitive Impairment - Pipeline by Boehringer Ingelheim GmbH, H2 2015 20
Mild Cognitive Impairment - Pipeline by CereSpir Incorporated, H2 2015 21
Mild Cognitive Impairment - Pipeline by D-Pharm Ltd., H2 2015 22
Mild Cognitive Impairment - Pipeline by Eisai Co., Ltd., H2 2015 23
Mild Cognitive Impairment - Pipeline by Eli Lilly and Company, H2 2015 24
Mild Cognitive Impairment - Pipeline by Octapharma AG, H2 2015 25
Mild Cognitive Impairment - Pipeline by Sage Therapeutics, H2 2015 26
Mild Cognitive Impairment - Pipeline by Sanofi, H2 2015 27
Mild Cognitive Impairment - Pipeline by Suven Life Sciences Ltd., H2 2015 28
Assessment by Monotherapy Products, H2 2015 29
Number of Products by Stage and Target, H2 2015 31
Number of Products by Stage and Mechanism of Action, H2 2015 33
Number of Products by Stage and Route of Administration, H2 2015 35
Number of Products by Stage and Molecule Type, H2 2015 37
Mild Cognitive Impairment Therapeutics - Recent Pipeline Updates, H2 2015 69
Mild Cognitive Impairment - Dormant Projects, H2 2015 82
Mild Cognitive Impairment - Dormant Projects (Contd..1), H2 2015 83
Mild Cognitive Impairment - Discontinued Products, H2 2015 84
List Of Figures
Number of Products under Development for Mild Cognitive Impairment, H2 2015 10
Number of Products under Development for Mild Cognitive Impairment - Comparative Analysis, H2 2015 11
Number of Products under Development by Companies, H2 2015 12
Number of Products under Investigation by Universities/Institutes, H2 2015 13
Comparative Analysis by Clinical Stage Development, H2 2015 14
Comparative Analysis by Early Stage Products, H2 2015 15
Assessment by Monotherapy Products, H2 2015 29
Number of Products by Top 10 Targets, H2 2015 30
Number of Products by Stage and Top 10 Targets, H2 2015 30
Number of Products by Top 10 Mechanism of Actions, H2 2015 32
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 32
Number of Products by Routes of Administration, H2 2015 34
Number of Products by Stage and Routes of Administration, H2 2015 34
Number of Products by Molecule Types, H2 2015 36
Number of Products by Stage and Molecule Types, H2 2015 36
